FLT3 and acute myeloid leukemia: For example, there is considerable interest in combining venetoclax with FLT3 inhibitors to improve outcomes in AML, and these drugs may impair the function of OATP1B1 and cause unanticipated DDIs that can remain unnoticed, compromising the safety of such combinatorial modalities.